Sartorius Stedim Biotech purchases Scottish company BioOutsource for an undisclosed sum
Sartorius Stedim Biotech has acquired BioOutsource, a privately owned company, based in Glasgow, UK, which has been operating in the biotechnology market since 2007 and generated revenues of €9m in the last 12 months. Both parties agreed not to disclose any further details about the transaction.
BioOutsource provides contract testing services to global biopharmaceutical clients to monitor the safety and quality of biologic drugs and vaccines. In particular, the company offers a comprehensive suite of services for the fast-growing biosimilar industry.
Its assays are used in the early phases of drug characterisation and comparability and for the lot release testing of novel therapeutics. This acquisition will develop SSB’s service offering throughout the drug development pathway.
Reinhard Vogt, a member of SSB’s board, commented: ‘By adding contract testing services, we will be able to support our biopharmaceutical clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases, and facilitate lot release testing in large-scale manufacturing. The highly qualified team at BioOutsource will complement our expertise, and we are looking forward to working with them.’
‘We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech, we will be able to scale our business to the next level and invest in new adjacent services,’ said Gerry MacKay, CEO of BioOutsource. ‘As a part of this group, we will have the opportunity to work with more international customers, particularly in areas like the United States and Asia, where there is significant investment in biosimilar development and manufacturing.’